Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants April 26, 2024
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) April 25, 2024
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules April 25, 2024